Neuromeka is showing strong performance. It appears that the news of being selected as the lead company for an international joint research and development (R&D) project overseen by the Korea Institute for Advancement of Technology (KIAT) under the Ministry of Trade, Industry and Energy is influencing the stock price.
As of 10 a.m. on the 12th, Neuromeka is trading at 23,200 KRW, up 6.67% from the previous day.
Neuromeka, together with Professor Hasehoon and Professor Gahhee Kim’s research team from Georgia Institute of Technology (Georgia Tech) in the U.S., is promoting the development of a medical assistive humanoid robot through a five-year international joint research project worth 10 billion KRW. Alongside Neuromeka, the Electronics and Telecommunications Research Institute (ETRI) and the Korea Advanced Institute of Science and Technology (KAIST) are participating, aiming to secure interactive customized HRI (Human-Robot Interaction), semantic autonomous driving, and dual-arm autonomous manipulation technologies based on AI technology.
Neuromeka and domestic research institutions are responsible for developing the robot platform and control base technologies, while Georgia Tech is in charge of preliminary research for applying the latest robotics artificial intelligence (AI) technologies. Neuromeka will directly develop and produce the entire humanoid robot finished product, including components such as motors and reducers. The goal is to commercialize it as soon as possible.
The medical AI humanoid robot will autonomously navigate within hospitals, assisting medical personnel (doctors and nurses) with their tasks, as well as supporting patients’ daily lives, providing emotional interaction and psychological stability. Through demonstration tests in actual hospitals, the project plans to stabilize the technology and commercialize the product, with Yonsei University Medical Center, Seoul Rehabilitation Hospital, and Daejeon Eulji University Hospital expressing interest in participating in the demonstrations.
Park Jonghoon, CEO of Neuromeka, stated, "Neuromeka has set entering the medical robot field as an important future goal," adding, "Through this project, we aim to solve problems that existing collaborative robots could not address with a new coexistence-type mobile manipulator."
He continued, "We expect that medical AI humanoid robot technology will greatly contribute to providing customized services in medical settings and reducing the daily workload of healthcare workers."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
